A comparison of newer drug treatments for urinary incontinence

Hospital Pharmacist

Volumn 9, Issue 3, 2002, Pages 69-75

  Booth, Carl ^a   Pascoe, Debbie ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; COLESTIPOL; COLESTYRAMINE; DOMPERIDONE; LEVODOPA; METOCLOPRAMIDE; MUSCARINIC AGENT; NEUROLEPTIC AGENT; OXYBUTYNIN; PHENOTHIAZINE DERIVATIVE; PROPIVERINE; TOLTERODINE; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT; TROSPIUM CHLORIDE;

ABDOMINAL DISCOMFORT; BLADDER INSTABILITY; CLINICAL TRIAL; CONSTIPATION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG INFORMATION; HEADACHE; HUMAN; PRESCRIPTION; REVIEW; SUSTAINED RELEASE PREPARATION; URINE INCONTINENCE; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0036129635     PISSN: 13527967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Managing incontinence due to detrusor instability
2. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin
3. The mechanism of action of tolterodine
4. Trospium chloride: An effective option for medical treatment of bladder overactivity
5. Prospective randomised controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the OBJECT study
6. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence
7. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence
8. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence
9. Efficacy and safety of propiverine in SCI patients suffering from detrusor hyper-reflexia
10. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms
11. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder
12. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis
13. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder
14. Tolterodine once-daily: Superior efficacy and tolerability in the treatment of the overactive bladder
15. Efficacy of trospium chloride in patients with detrusor instability: A placebo-controlled, randomised, double-blind, multicentre clinical trial
16. Trospium chloride vs oxybutynin: A randomised, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia
17. A comparison of trospium chloride and oxybutynin in the treatment of the overactive bladder - A randomised, double-blind study
18. Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge syndrome: A double-blind, placebo controlled, multicentre clinical trial
19. Tolerability and efficacy of trospium chloride in a long term treatment (52 weeks) in patients with urge-syndrome: A double-blind, controlled, multicentre clinical trial